-
Mon, 9th November 2026 10:04 am
Q1 Financials(Q1 Un-audited): Consolidated EPS was Tk. 8.87 for July-September 2026 as against Tk. 6.47 for July-September 2025. Consolidated NOCFPS was Tk. 21.98 for July-September 2026 as against Tk. 12.62 for July-September 2025. Consolidated NAV per share was Tk. 339.31 as on September 30, 2026 and Tk. 329.19 as on June 30, 2026. (cont.1)
-
Mon, 9th November 2026 10:04 am
Q1 Financials(Cont. News of RENATA): Reasons for deviation: The Group's net profit for the quarter increased significantly compared to the corresponding quarter of the previous year, primarily attributable to revenue growth and a reduction in net finance expenses. The lower net finance expenses reflect the favorable impact of capital restructuring initiatives and prudent management of foreign exchange and interest rate risks. (cont.2)
-
Mon, 9th November 2026 10:04 am
Q1 Financials(Cont. News of RENATA): As the number of ordinary shares remained unchanged year-on-year, the increase in net profit resulted in a corresponding improvement in earnings per share (EPS). Net operating cash flow per share (NOCFPS) increased significantly during the first quarter compared to the corresponding period of the previous year, primarily driven by higher operating profit and supported by favorable working capital movements. (cont.3)
-
Mon, 9th November 2026 10:04 am
Q1 Financials(Cont. News of RENATA): The working capital contribution was mainly attributable to a reduction in cash tied up in inventories and a favorable movement in trade and other payables, partially offset by increased cash utilization in trade and other receivables. (end)
-
Sun, 1st November 2026 11:25 am
Board Meeting schedule under LR 16(1)As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on November 08, 2026 at 2:30 PM to consider, among others, Un-Audited Financial Statements for the First Quarter (Q1) period ended September 30, 2026.
-
Sun, 18th October 2026 10:05 am
Dividend DeclarationThe Board of Directors has recommended 55% Cash Dividend for the year ended June 30, 2026. Date of AGM: 19.12.2026, Time: 11:30 AM, Venue: Digital Platform. Record Date: 15.11.2026. The Company has also reported Consolidated EPS of Tk. 31.76, Consolidated NAV per share of Tk. 329.19 and Consolidated NOCFPS of Tk. 49.88 for the year ended 30-Jun-2026 as against Consolidated EPS of Tk. 19.36, Consolidated NAV per share of Tk. 305.49 and Consolidated NOCFPS of Tk. 41.16 for the year ended 30-Jun-2025.
-
Sun, 18th October 2026 10:05 am
Price Limit OpenThere will be no price limit on the trading of the shares of the Company today (18.10.2026) following its corporate declaration.
-
Sun, 18th October 2026 10:05 am
Update of InformationThe Company has requested the shareholders to check and update their BOID's e-mail address, mobile number and Bank A/c details along with Routing Number to get Dividend online through BEFTN system.
-
Tue, 6th October 2026 12:45 pm
Change of Board Meeting Time under LR 19(1)The Company has further informed that, the Board meeting under LR 19(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, will be held on October 17, 2026 at 2:30 PM instead of 12:30 PM to consider, among others, audited financial statements of the Company for the year ended June 30, 2026.
-
Mon, 5th October 2026 10:25 am
Board Meeting schedule under LR 19(1)As per Regulation 19(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on October 17, 2026 at 12:30 PM to consider, among others, audited financial statements of the Company for the year ended June 30, 2026.
-
Tue, 15th September 2026 04:11 pm
Credit Rating ResultAlpha Credit Rating PLC. has assigned Surveillance rating of the Company as "AAA" in the long term and "ST-1" in the short term along with Stable outlook based on audited financial statement for the year ended 30 June of FY 2024-2025, unaudited financial statement for the 3rd quarter ended March 2026 and relevant qualitative information till 14 September, 2026.
-
Thu, 6th August 2026 10:05 am
Company exports first Therapeutics consignment to PortugalThe company has informed that it has expanded its presence in the European market by dispatching its first consignment of therapeutics to Portugal. The initial launch includes Amantadine 100 mg capsules, manufactured at EU-GMP-approved Rajendrapur General Facility, alongside Fludrocortisone 0.1 mg tablets & Cabergoline 0.5 mg tablets, produced at EU-GMP-approved Mirpur Potent Facility. This entry into Portugal represents a significant step in Renata's ongoing international expansion strategy across Europe.
-
Thu, 2nd July 2026 10:15 am
Renata PLC Secures European approval for Thyrox (Levothyroxine)The company has informed that it has received approval for its Levothyroxine Sodium tablets under the EU Decentralised Procedure (DCP) in Ireland, Germany, Italy, Poland, Portugal and Malta. The product will be manufactured at Renata's EU GMP-approved potent product facility. Renata PLC intends to support safe and reliable access to Levothyroxine in the newly approved EU markets.
-
Thu, 30th April 2026 10:05 am
Q3 Financials(Q3 Un-audited): Consolidated EPS was Tk. 6.81 for January-March 2026 as against Tk. 5.12 for January-March 2025; Consolidated EPS was Tk. 20.39 for July 2025-March 2026 as against Tk. 15.95 for July 2024-March 2025. Consolidated NOCFPS was Tk. 22.40 for July 2025-March 2026 as against Tk. 21.76 for July 2024-March 2025. Consolidated NAV per share was Tk. 320.02 as on March 31, 2026, and Tk. 305.49 as on June 30, 2025.
-
Wed, 22nd April 2026 12:14 pm
Board Meeting schedule under LR 16(1)As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on April 29, 2026 at 2:30 PM to consider, among others, Un-Audited Financial Statements for the Third Quarter (Q3) period ended March 31, 2026.
